Medical professionals

Why a non-invasive prenatal test?

Non-invasive prenatal tests can prevent the need for about 98% of invasive tests in patients at risk for T211.

* The current standard for detecting prenatal chromosomal alterations requires
the use of invasive techniques (amniocentesis and chorionic villus biopsy), which carry a risk between 0.5%-2% of spontaneous abortion.

* NACE® provides reliable information which avoids the need for unnecessary invasive techniques.

Coverage of the NACE® test for single pregnancies ordered by their importance

Coverage of the NACE® test for single pregnancies ordered by their importance

According to data from the 2012 European Registry for Prenatal Diagnosis2, abnormalities
in chromosomes 21, 18, and 13 represent 71% of all chromosomal alterations detected.

Detection rate according to the type of screening

Type of screening

NACE®2

1sttrimester
combined screening*

Extended combined screening**

Gestational age

From week 10
9-13 weeks
11-13 weeks

Detection rate

99,92% (FP<0.1%)
T21/T18/T13
80-85% (FP 5%)
85-93% (FP 2.5%)

* Includes maternal age, nuchal translucency measurement, and the detection of the PAPP-A and free B-HCG biochemical markers.
** Includes other ultrasound markers: nasal bone absence, assessment of the ductus venosus, and tricuspid blood flow. (FP = false positives).

As per PCPNDT guidelines, sexing status of the analyzed sample is never revealed in the report neither in any other way to the couple or clinician.